Highlights on the morphology, prognostic factors, diagnostics, and treatment (chemotherapy, chemotherapy + radiation, targeted therapy, immunotherapy, and surgery) in small cell lung cancer

Abstract

The article present a review and experience from a a single institution on the morphology, diagnostics, and treatment (chemotherapy, radiation, targeted therapy, and immunotherapy)) of small cell lung cancer (SCLC). The characteristic molecular, genetic, histological, and immunohistochemical features of NSCLC and SCLC are compared. An important issue of SCLC histogenesis is highlighted, taking into account its neuroendocrine characteristics. Paraneoplastic syndromes associated with SCLC and other clinical features of SCLC are discussed. The algorithm of examination of a patient with histologically or cytologically confirmed SCLC, staging schemes, and main prognostic factors are presented. The following aspects of chemoradiotherapy of localized SCLC are considered: features of “early,” ”late,” simultaneous, and sequential therapy, and the need for whole brain radiotherapy in patients with localized and extensive SCLC. The article discusses the treatment algorithm for extensive disease SCLC, taking into account the recent success of chemoimmunotherapy in the first-line treatment of SCLC. As is known, the combinations of atezolizumab, etoposide, carboplatin and durvalumab, etoposide, cisplatin, or carboplatin showed a real benefit compared to chemotherapy alone. Although the second line treatment has not changed, it is now possible to prescribe a third line therapy because of the proven effectiveness of immunotherapy. Targeted therapy, although not shown to be effective in SCLC, is discussed in terms of the key features of genetic alterations as a possible target for therapy. An important issue in the treatment of patients with superior vena cava syndrome is considered separately. The tasks of future prospective research in SCLC are described.

Keywords

small cell lung cancer / morphology / diagnostics and treatment / localized disease small cell lung cancer / extensive disease small cell lung cancer / chemotherapy, chemoradiotherapy and immunotherapy of small cell lung cancer / surgical treatment of small cell lung cancer

References

[1] Bychkov MB. Small cell lung cancer. Moscow: Pharmarus Print Media; 2013. (In Russ).

[2] Мелкоклеточный рак легкого / под ред. М.Б. Бычкова. Москва: Фармарус Принт Медиа, 2013.

[3] Imyanitov YN. Epidemiology and biology of NETs. Prakticheskaya onkologiya. 2005;(6):4. (In Russ).

[4] Имянитов Е.Н. Эпидемиология и биология НЭО // Практическая онкология. 2005. № 6. С. 4.

[5] Hanrahan EO. Small cell carcinoma of the lung. In: Stewart D.J., editor. Lung Cancer: Prevention, Management and, Emerging Therapies. Humana press. 2010;395–434.

[6] Hanrahan E.O. Small cell carcinoma of the lung // Stewart D.J., editor. Lung Cancer: Prevention, Management and, Emerging Therapies. Humana press. 2010. P. 395–434.

[7] National Comprehensive Cancer Network. NCCN Guidelines. Version 2019. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx. Access: Dec 02, 2020.

[8] National Comprehensive Cancer Network. NCCN Guidelines. Version 2019. [Электронный ресурс]. Режим доступа: https://www.nccn.org/professionals/physician_gls/default.aspx. Дата обращения: 02.12.2020.

[9] Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T. Pembrolizumab or placebo plus etoposide and platinum (EP) as front-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J. Clin. Oncol. 2020;38(21):2369–79.

[10] Rudin C.M., Awad M.M., Navarro A., Gottfried M., Peters S., Csőszi T. Pembrolizumab or placebo plus etoposide and platinum (EP) as front-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study // J. Clin. Oncol. 2020. Vol. 38. N 21. P. 2369–79.

[11] Lyubimova NV, Kushlinski NE. Biochemical markers of SCLC and paraneoplastic syndromes. In: Bychkov MB, editor. Small cell lung cancer. Moscow: Pharmarus Print Media; 2013. (In Russ.)

[12] Любимова Н.В., Кушлинский Н.Е. Биохимические маркеры МРЛ и паранеопластические синдромы // Мелкоклеточный рак легкого / под ред. М.Б. Бычкова. М.: Фармарус Принт Медиа, 2013.

[13] Slotman B, van Tinteren H, Praag J, Knegjens J, El Sharouni S, Hatton M, et al. Use of thoracic radiotherapy for extensive stage SCLC: a phase 3 randomized controlled trial. Lancet. 2015;385:36–42. DOI: 10.1016/S0140-6736(14)61085-0.

[14] Slotman B., van Tinteren H., Praag J., Knegjens J., El Sharouni S., Hatton M., et al. Use of thoracic radiotherapy for extensive stage SCLC: a phase 3 randomized controlled trial // Lancet. 2015. Vol. 385. P. 36–42. DOI: 10.1016/S0140-6736(14)61085-0.

[15] Trigo J, Subbiah V, Besse B, Moreno V, López R, Salaet MA, et al. Lurbinectedin as second-line treatment for patients with SCLC. Lancet oncol. 2020;21(5):645–54. DOI: 10.1016/S1470-2045(20)30068-1.

[16] Trigo J., Subbiah V., Besse B., Moreno V., López R., Salaet M.A., et al. Lurbinectedin as second-line treatment for patients with SCLC // Lancet oncol. 2020. Vol. 21. N5. P. 645–54. DOI: 10.1016/S1470-2045(20)30068-1.

RIGHTS & PERMISSIONS

Eco-Vector